Literature DB >> 17072305

A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms.

Jeremy Hall1, Heather C Whalley, Dominic E Job, Ben J Baig, Andrew M McIntosh, Kathryn L Evans, Pippa A Thomson, David J Porteous, David G Cunningham-Owens, Eve C Johnstone, Stephen M Lawrie.   

Abstract

NRG1, encoding neuregulin 1, is a susceptibility gene for schizophrenia, but no functional mutation causally related to the disorder has yet been identified. Here we investigate the effects of a variant in the human NRG1 promoter region in subjects at high risk of schizophrenia. We show that this variant is associated with (i) decreased activation of frontal and temporal lobe regions, (ii) increased development of psychotic symptoms and (iii) decreased premorbid IQ.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17072305     DOI: 10.1038/nn1795

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN: 1097-6256            Impact factor:   24.884


  95 in total

Review 1.  The contribution of GABAergic dysfunction to neurodevelopmental disorders.

Authors:  Kartik Ramamoorthi; Yingxi Lin
Journal:  Trends Mol Med       Date:  2011-04-21       Impact factor: 11.951

2.  Brain vs behavior: an effect size comparison of neuroimaging and cognitive studies of genetic risk for schizophrenia.

Authors:  Emma Jane Rose; Gary Donohoe
Journal:  Schizophr Bull       Date:  2012-04-12       Impact factor: 9.306

3.  Genetic variation in G72 correlates with brain activation in the right middle temporal gyrus in a verbal fluency task in healthy individuals.

Authors:  Axel Krug; Valentin Markov; Sören Krach; Andreas Jansen; Klaus Zerres; Thomas Eggermann; Tony Stöcker; N Jon Shah; Markus M Nöthen; Alexander Georgi; Jana Strohmaier; Marcella Rietschel; Tilo Kircher
Journal:  Hum Brain Mapp       Date:  2011-01       Impact factor: 5.038

Review 4.  Genetic neuropathology of schizophrenia: new approaches to an old question and new uses for postmortem human brains.

Authors:  Joel E Kleinman; Amanda J Law; Barbara K Lipska; Thomas M Hyde; Justin K Ellis; Paul J Harrison; Daniel R Weinberger
Journal:  Biol Psychiatry       Date:  2011-01-15       Impact factor: 13.382

5.  Optimisation of anti-psychotic therapeutics: a balancing act?

Authors:  A J Lawrence
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

6.  MRI brain volume abnormalities in young, nonpsychotic relatives of schizophrenia probands are associated with subsequent prodromal symptoms.

Authors:  Beng-Choon Ho
Journal:  Schizophr Res       Date:  2007-08-29       Impact factor: 4.939

Review 7.  Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway.

Authors:  Chao Deng; Bo Pan; Martin Engel; Xu-Feng Huang
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

8.  Reversible overexpression of bace1-cleaved neuregulin-1 N-terminal fragment induces schizophrenia-like phenotypes in mice.

Authors:  Xiaoyang Luo; Wanxia He; Xiangyou Hu; Riqiang Yan
Journal:  Biol Psychiatry       Date:  2013-10-05       Impact factor: 13.382

9.  Effects of schizophrenia risk variation in the NRG1 gene on NRG1-IV splicing during fetal and early postnatal human neocortical development.

Authors:  Clare Paterson; Yanhong Wang; Joel E Kleinman; Amanda J Law
Journal:  Am J Psychiatry       Date:  2014-09       Impact factor: 18.112

10.  Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice.

Authors:  A V Savonenko; T Melnikova; F M Laird; K-A Stewart; D L Price; P C Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.